British Drug Firm Gets Approval For Long-Term Use of Its Blood Thinner Drug From USFDA

Patients with history of heart attack can now be treated with 60 mg of Brilinta twice daily along with a daily maintenance dose of aspirin beyond that first year.

A new dose of blood thinner Brilinta by AstraZeneca Plc that is intended for longer-term use in patients with a history of heart attack or a condition known as acute coronary syndrome (ACS) has been approved by the U.S. Food and Drug Administration.

The FDA approved Brilinta tablets at a new 60 milligram dose that would be taken along with aspirin beyond a year after a heart attack. The drug, which is used to prevent blood clots that can cause heart attacks, strokes and deaths, had previously been approved at a higher dose for use during the first year after acute coronary syndrome.

US FDA Approves an Injectable Anti-Cholesterol Drug called Repatha
Repatha provides another treatment option for patients with hypercholesterolemia who have not been able to lower their LDL cholesterol enough with statins.

For the first year following an ACS event Brilinta is recommended for administration as 90-mg doses, two times a day. After one year the dose can be reduced to 60 mg. The drug can be used alongside a daily dose of 75 to 100 mg aspirin for maximum effect. The FDA move could help increase sales of the heart drug and the numbers of patients eligible for the medicine to include those who had a heart attack more than a year ago.

Brilinta interferes with platelet activation. Based on studies, Brilinta was found to be more effective than clopidogrel at least for the first year following ACS, making it the first oral antiplatelet approved by the FDA to beat clopidogrel in reducing cardiovascular deaths. Brilinta also minimizes stent thrombosis in those who received stenting to treat ACS.

"We know that patients remain at risk beyond the first year after their heart attack," said Elisabeth Bjork, AstraZeneca's head of cardiovascular and metabolic diseases.

U.S. FDA Clears MagVita TMS Therapy System for Major Depressive Disorder
Major depressive disorder is characterized by a persistent low mood that is accompanied by low self-esteem and by a loss of interest in normally enjoyable activities.

Reports say that 60-mg Brilinta tablets will be made available in pharmacies by the end of September.

Source-Medindia

Advanced Technology: U.S. FDA Approves Eko Devices� Eko Core Digital Stethoscope
This is probably one of the most important innovations in the plain old stethoscope in recent years,” said Dr. Charanjit Rihal at the Mayo Clinic.

Indian Pharma Gets USFDA Approval To Market Tablets To Treat Osteoporosis In The US
The approval for Aurobindo Pharma’s Raloxifene Hydrochloride tablets is for strength of 60 mg that is therapeutically equivalent to Evista, 60 mg of Eli Lilly.